Novus Biologicals, a Bio-Techne brand’s Post

Tomorrow is the last day for voting! If our products and services have served you well, nominate Bio-Techne for CiteAb Researchers’ Choice Award. Voting closes February 21, 2024. #CiteAbAwards2024 #CiteAbAwards24 #CiteAbAwards #antibodies #proteins #RNAscope #ELISAKits #smallmolecules #cellbiology

Tomorrow is the last day for voting! If our products and services have served you well, nominate Bio-Techne for CiteAb Researchers’ Choice Award. Voting closes February 21, 2024. #CiteAbAwards2024 #CiteAbAwards24 #CiteAbAwards #antibodies #proteins #RNAscope #ELISAKits #smallmolecules #cellbiology

Tomorrow is the last day for voting! If our products and services have served you well, nominate Bio-Techne for CiteAb Researchers’ Choice Award. Voting closes February 21, 2024. #CiteAbAwards2024 #CiteAbAwards24 #CiteAbAwards #antibodies #proteins #RNAscope #ELISAKits #smallmolecules #cellbiology

Helix's CEO, Mr. Josh Carter, continues his participation at the American Crystallographic Association's 74th Annual Meeting in Denver, Colorado, from July 7-12, 2024 ( https://loom.ly/OCLftGM ). The second day has been fantastic, with morning and afternoon sessions covering topics in structural sciences, Cryo-ET, and Hot Structures, to name a few. Two standout talks include “Unveiling the Molecular Interplay of VPS34 Inhibition by Novel Drug Targets: A Promising Approach for Tailored Cancer Therapeutics” from Brigham Young University, and “Development of Constructs and Crystal Forms of HSP47 to Support Structure-Based Drug Design” by Bristol-Myers Squibb. The day is packed with phenomenal sessions, and our CEO, Mr. Josh Carter, is eager to connect with both old and new friends, clients, and colleagues for meaningful conversations about today’s topics and overcoming challenges in these fields. Be sure to look for him! Did you know... Our gene-to-protein expression, isolation, crystallization, and structural determination services are crucial for the success of many projects? Our clients rely on us to deliver the quality results they need to achieve their goals. Contact us today and let us help you achieve your goals! (https://loom.ly/tDP9lr8) #cryoem #crystallization #crystallography #drugdiscovery #drugdesign #protein #proteins #dna #rna #antibody #antibodies #science #nature #research #bio #bionetwork #biotechnology #biotech #bioscience #biotechnologyindustry #biopharma #drugdesign #drugdevelopment #pharmaceuticals #pharma #drug #lifesciences #lifescience

Now accepting! Upcoming special issue entitled "(Multi)Omics approaches in atherosclerosis", in Vascular Pharmacology (Elsevier) accepts new research articles on (multi)omics approaches in atherosclerosis. The special issue is organized by the AtheroNET consortium (#COSTActionCA21153 - #COST). COST Action AtheroNET is a Network for implementing multiomic approaches in atherosclerotic cardiovascular disease prevention and research. Manuscripts as an original work, review, or opinion paper are due by 30.6.2024. For full special issue scope: https://lnkd.in/ekUKtRgi or or contact one of the guest editors Miron Sopic, Tijana Mitić, Judith Sluimer or Yvan Devaux There will be a fast peer-review and publication process for this special issue. The journal supports both open-access and subscription articles, so you can choose what is best for you. Vascular Pharmacology already has an Impact Factor of 4 and a CiteScore of 9.2. We hope you will consider contributing to the success of this special issue by submitting an article.

🎉 Exciting Milestone Alert! 🎉 I am thrilled to share that my research on tumor markers in cirrhosis and HCC has reached a significant milestone - a hundred reads! 📚🔬 It's truly humbling to see the interest and engagement surrounding this important area of study. Cirrhosis and hepatocellular carcinoma (HCC) pose significant challenges in healthcare, and understanding tumor markers is crucial for early detection, prognosis, and treatment strategies. Through my research, I aim to shed light on novel biomarkers and their potential implications for patients with these conditions. I am grateful for the support of my colleagues, collaborators, and the scientific community at large for their interest in my work. This milestone serves as a reminder of the importance of our collective efforts in advancing knowledge and improving patient outcomes. Thank you to everyone who has contributed to the success of this research endeavor. Let's continue to push boundaries, ask critical questions, and work towards a future where effective diagnostic and therapeutic strategies are available for all those affected by cirrhosis and HCC. #Research #TumorMarkers #Cirrhosis #HCC #MedicalScience #Healthcare #ScientificDiscovery #MedicalResearch #LiverHealth #Oncology #CancerResearch #BiomedicalScience #HealthScience #AcademicResearch #MedicalInnovation #ScientificCommunity #Medicine #HealthcareDiscovery #AcademicAchievement #HealthTech #BioMarkers #ScientificProgress #LiverCancer #ScienceCommunication #WomenInMedicine 🌟🔍